Predictors of outcome and comparison of different drug regimens for the prevention of relapse in patients with Graves' disease

European Journal of Endocrinology

Volumn 147, Issue 5, 2002, Pages 583-589

  Nedrebøo, Bjørn G ^a,e   Holm, Pål ^a   Uhlving, Sverre ^c   Sørheim, Jan Inge ^d   Skeie, Svein ^c   Eide, Geir Egil ^a   Husebye, Eystein S ^a   Lien, Ernst A ^b   Aanderud, Sylvi ^a  

^a UNIVERSITY OF BERGEN   (Norway)

^b HAUKELAND UNIVERSITY HOSPITAL   (Norway)

^c STAVANGER UNIVERSITY HOSPITAL   (Norway)

^d Stord Hospital   (Norway)

^e HAUGESUND HOSPITAL   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

ANTITHYROID AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CARBIMAZOLE; LEVOTHYROXINE; PROPYLTHIOURACIL; THYROTROPIN RECEPTOR ANTIBODY;

ADOLESCENT; ADULT; AGED; AGRANULOCYTOSIS; ARTHROPATHY; ARTICLE; BIOCHEMISTRY; CIGARETTE SMOKING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG RESPONSE; DRUG WITHDRAWAL; FEMALE; GASTROINTESTINAL SYMPTOM; GRAVES DISEASE; HAIR LOSS; HUMAN; LABORATORY TEST; LIVER TOXICITY; MAJOR CLINICAL STUDY; MALE; PREDICTION; PRIORITY JOURNAL; PROSPECTIVE STUDY; PRURITUS; RANDOMIZED CONTROLLED TRIAL; RASH; RECURRENT DISEASE; SYMPTOMATOLOGY; THROMBOCYTOPENIA; TREATMENT OUTCOME;

ANTIBODIES; ANTITHYROID AGENTS; DRUG COMBINATIONS; GRAVES DISEASE; HUMANS; PROGNOSIS; PROSPECTIVE STUDIES; RECEPTORS, THYROTROPIN; RECURRENCE; SMOKING; THYROXINE; TREATMENT OUTCOME;

EID: 0036856366     PISSN: 08044643     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. Weetman AP & McGregor AM. Autoimmune thyroid disease: further developments in our understanding. Endocrine Reviews 1994 15 788-830.
2. Bjøro T, Holmen J, Krüger Ø, Midthjell K, Hunstad K, Schreiner T et al. Prevalence of thyroid disease, thyroid dysfunction and thyroid peroxidase antibodies in a large, unselected population. The Health Study of Nord-Trøndelag (HUNT). European Journal of Endocrinology 2000 143 639-647.
3. Raber W, Kmen E, Waldhäusl W & Vierhapper H. Medical therapy of Graves' disease: effect on remission rates of methimazole alone and in combination with triiodothyronine. European Journal of Endocrinology 2000 142 117-124.
4. Glinoer D, Hesch D, Lagasse R & Laurberg P. The management of hyperthyroidism due to Graves' disease in Europe in 1986. Results of an international survey. Acta Endocrinologica 1987 285 (Suppl) 3-23.
5. Maugendre D, Gatel A, Campion L, Massart C, Guilhem I, Lorcy Y et al. Antithyroid drugs and Graves' disease - prospective randomized assessment of long-term treatment. Clinical Endocrinology 1999 50 127-132.
6. Romaldini JH, Bromberg N, Werner RS, Tanaka LM, Rodrigues HF, Werner MC et al. Comparison of effects of high and low dosage regimens of antithyroid drugs in the management of Graves' hyperthyroidism. Journal of Clinical Endocrinology and Metabolism 1983 57 563-570.
7. Jorde R, Ytre-Arne K, Størmer J & Sundsfjord J. Short-term treatment of Graves' disease with methimazole in high versus low doses. Journal of Internal Medicine 1995 238 161-165.
8. Hashizume K, Ichikawa K, Sakurai A, Suzuki S, Takeda T, Kobayashi M et al. Administration of thyroxine in treated Graves' disease. Effects on the level of antibodies to thyroid-stimulating hormone receptors and on the risk of recurrence of hyperthyroidism. New England Journal of Medicine 1991 324 947-953.
9. Allannic H, Fauchet R, Orgiazzi J, Madec AM, Genetet B, Lorcy Y et al. Antithyroid drugs and Graves' disease: a prospective randomized evaluation of the efficacy of treatment duration. Journal of Clinical Endocrinology and Metabolism 1990 70 675-679.
10. Edmonds CJ & Tellez M. Treatment of Graves' disease by carbimazole: high dose with thyroxine compared with titration dose. European Journal of Endocrinology 1994 131 120-124.
11. McIver B, Rae P. Beckett G, Wilkinson E, Gold A & Toft A. Lack of effect of thyroxine in patients with Graves' hyperthyroidism who are treated with an antithyroid drug. New England Journal of Medicine 1996 334 220-224.
12. Lucas A, Salinas I, Rius F, Pizarro E, Granada ML, Foz M et al. Medical therapy of Graves' disease: does thyroxine prevent recurrence of hyperthyroidism? Journal of Clinical Endocrinology and Metabolism 1997 82 2410-2413.
13. Glinoer D, de Nayer P & Bex M. Effects of L-thyroxine administration. TSH-receptor antibodies and smoking on the risk of recurrence in Graves' hyperthyroidism treated with antithyroid drugs: a double-blind prospective randomized study. European Journal of Endocrinology 2001 144 475-483.
14. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. Journal of the American Statistical Association 1958 53 457-481.
15. Mantel N. Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemotherapy Report 1966 50 163-170.
16. Cox DR. Regression models and life-tables. Journal of the Royal Statistical Society 1972 34 187-220.
17. Rittmaster RS, Abbott EC, Douglas R, Givner ML, Lehmann L, Reddy S et al. Effect of methimazole, with or without L-thyroxine, on remission rates in Graves' disease. Journal of Clinical Endocrinology and Metabolism 1998 83 814-818.
18. Wiersinga WM. Immunosuppression of Graves' hyperthyroidism - still an elusive goal. New England Journal of Medicine 1996 334 265-266.
19. Corrales JJ, Lopez A, Ciudad J, Mories MT, Miralles JM & Orfao A. Methimazole therapy in Graves' disease influences the abnormal expression of CD69 (early activation antigen) on T cells. Journal of Endocrinology 1997 155 491-500.
20. Reinwein D, Benker G, Lazarus JH & Alexander WD. A prospective randomized trial of antithyroid drug dose in Graves' disease therapy. European Multicenter Study Group on Antithyroid Drug Treatment. Journal of Clinical Endocrinology and Metabolism 1993 76 1516-1521.
21. Paschke R, Vogg M, Kristoferitsch R, Aktuna D, Wawschinek O, Eber O et al. Methimazole has no dose-related effect on the intensity of the intrathyroidal autoimmune process in relapsing Graves' disease. Journal of Clinical Endocrinology and Metabolism 1995 80 2470-2474.
22. Weetman AP. Graves' disease. New England Journal of Medicine 2000 343 1236-1248.
23. Feldt-Rasmussen U, Schleusener H & Carayon P. Meta-analysis evaluation of the impact of thyrotropin receptor antibodies on long term remission after medical therapy of Graves' disease. Journal of Clinical Endocrinology and Metabolism 1994 78 98-102.
24. Müller B, Zulewski H, Huber P, Ratcliffe JG & Staub JJ. Impaired action of thyroid hormone associated with smoking in women with hypothyroidism. New England Journal of Medicine 1995 333 964-969.
25. Ericsson UB & Lindgärde F. Effects of cigarette smoking on thyroid function and the prevalence of goitre, thyrotoxicosis and autoimmune thyroiditis. Journal of Internal Medicine 1991 229 67-71.
26. Utiger RD. Cigarette smoking and the thyroid. New England Journal of Medicine 1995 333 1001-1002.
27. Vestergaard P. Smoking and thyroid disorders - a meta-analysis. European Journal of Endocrinology 2002 146 153-161.
28. Allahabadia A, Daykin J, Holder RL, Sheppard MC, Gough SC & Franklyn JA. Age and gender predict the outcome of treatment for Graves' hyperthyroidism. Journal of Clinical Endocrinology and Metabolism 2000 85 1038-1042.
29. Vitti P, Rago T, Chiovato L, Pallini S, Santini F, Fiore E et al. Clinical features of patients with Graves' disease undergoing remission after antithyroid drug treatment. Thyroid 1997 7 369-375.
30. Vitug AC & Goldman JM. Hepatotoxicity from antithyroid drugs. Hormone Research 1985 21 229-234.